AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 20(4), 1971, pp. 584-588
Copyright © 1971 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bell, W. J.
Right arrow Articles by Nassif, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bell, W. J.
Right arrow Articles by Nassif, S.

Comparison of Pyrantel Pamoate and Piperazine Phosphate in the Treatment of Ascariasis*

W. J. Bell AND Samir Nassif
International Medical Department, Pfizer International, Inc., New York, N. Y. 10017 and Qalyub Field Research Administration, Ministry of Public Health, U.A.R.

The effect of pyrantel pamoate was compared with that of piperazine phosphate in the treatment of ascariasis, the results being expressed in terms of quantitative egg counts. Pyrantel pamoate, in a single oral dose of 10.0 mg per kg of body weight, achieved a cure rate of 90% on day 3 and 100% on day 10 after treatment. Administration of 5.0 mg and 2.5 mg per kg similarly achieved early and pronounced reduction of egg output with a cure rate of 90% by day 10. In patients not cured, mean reduction of egg output was almost complete with the 10.0-mg treatment and 88% with the 2.5-mg treatment calculated throughout days 8, 9, and 10. Standard oral treatment with piperazine phosphate achieved a cure rate of 71% by day 10, significantly less than that with 2.5 mg of pyrantel pamoate. In patients not cured, a mean reduction in egg output of 72% was achieved, as calculated throughout days 1, 2, and 3, with no further improvement. Other than transient abdominal colic in a few patients during the early posttreatment period, no obvious drug-related symptoms were observed. No trend of abnormality was noted in either serum glutamic pyruvic transaminase or alkaline phosphatase levels after pyrantel pamoate treatment.

Accepted for publication February 1, 1971.


* The work upon which this article is based was done under the auspices of the Joint Medical Research Project sponsored by the Ministry of Public Health, U.A.R. and Pfizer Egypt, S.A.A.

Please address requests for reprints to The International Medical Director, Pfizer International, Inc., 235 East 42nd Street, New York, N. Y. 10017.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1971 by the American Society of Tropical Medicine and Hygiene.